hrp0097rfc2.6 | Bone, Growth Plate and Mineral Metabolism | ESPE2023

Short term side effects of first bisphosphonate infusion in children with different underlying bone pathologies.

Cheung Moira , Raimann Adalbert , Semler Oliver , Högler Wolfgang

Background: Bisphosphonates act to increase bone mass by inhibition of osteoclastic bone resorption and reduction of bone turnover. Since the successful use of bisphosphonates in children with osteogenesis imperfecta, a broad range of pediatric indications with variable underlying pathomechanism emerged. While the use of bisphosphonates appears to be safe in children, data on risk factors for acute-phase reaction are sparse. A systematic characterization of si...

hrp0097p1-6 | Adrenals and HPA Axis | ESPE2023

A retrospective analysis of children and youth with congenital adrenal hyperplasia treated with hydrocortisone modified-release hard capsules

Neumann Uta , von Mackensen Jolande , Lankes Erwin , Blankenstein Oliver

Context: Children with congenital adrenal hyperplasia (CAH) require hydrocortisone replacement from birth. The highest ACTH driven endogenous production of androgens happens in the early morning. To achieve a good therapy control, immediate release hydrocortisone is given early in the morning or late at night. In year 2021 the hydrocortisone modified-release hard capsule (Efmody®) was approved by the European medicine agency and from September 2021 it is l...

hrp0095rfc2.1 | Bone, Growth Plate and Mineral Metabolism | ESPE2022

Muscle function in XLH - Two year prospective observation of paediatric patients before and after treatment initiation with burosumab

Rehberg Mirko , Heistermann Johanna , Neuburg Lisa , Schönau Eckhard , Hoyer-Kuhn Heike-Katharina , Semler Oliver

X-linked hypophosphatemia (XLH, MIM 307800) is a rare hereditary disorder of bone metabolism characterized by growth impairment, leading to bone deformities and short stature and beside others to muscle function deficits. XLH is caused by defect of endopeptidase PHEX leading to high levels of FGF-23 and thereby renal phosphate wasting. While conventional treatment includes substitution of phosphate and 1-25 OH-Vitamin D, now a treatment with a FGF-23 antibody (burosumab) is av...

hrp0089p3-p383 | Thyroid P3 | ESPE2018

Corticosteroid Resistant Immune Thrombocytopenic Purpura, is it a Marker of Future Graves Disease?

Azcona Maria Cristina , Leon Jose Luis , Prados Monica , Ochotorena Amaia , Oliver Asier

Introduction: The Immune Thrombocytopenic Purpura (ITP) and Graves Disease (GD) have in common an autoinmune physiopathology. ITP is characterized by a platelet count less than 100 × 106/l in the absence of other cause. On one hand, ITP has been associated with thyroid dysfunction, without developing GD. On the other hand, GD might develop with moderate thrombocytopenia, generally more than 100×109/l. It is described that in most cases ITP might...

hrp0086fc15.3 | Late Breaking | ESPE2016

Contribution of Next Generation Sequencing Approach for Management of Congenital Hypothyroidism with Eutopic Thyroid Gland

Savagner Frederique , Gennero Isabelle , Edouard Thomas , Cartault Audrey , Tauber Maithe , Petit Isabelle Oliver

Background: Congenital hypothyroidism (CH) is referred to dyshormonogenesis for 15 to 30%. Homozygous mutations associated have been demonstrated in DUOX2, TPO, TG, SLC5A5 (NIS), SLC26A4 (Pendred), DUOXA2, and IYD (DEHAL1) genes.Objective and hypotheses: Previous studies focusing on one or few thyroid-specific genes have proved not to be comprehensive enough for understanding physiopathological mechanisms of HC with dyshormonogenesis. Emerging diagnostic...

hrp0086p1-p15 | Adrenal P1 | ESPE2016

Individualized Optimization with 17OHP-Saliva Profiles Leads to Changes in Hydrocortisone Dosing Pattern in Children with Congenital Adrenal Hyperplasia

Neumann Uta , Lankes Erwin , Bathelt-Tok Franziska , Krude Heiko , Blankenstein Oliver

Background: Treatment of CAH in children is compromised by the pharmacokinetic of available hydrocortisone (HC) preparations resulting in un-physiological early morning rise of ACTH followed by elevated androgens. HC substitution usually follows a fixed dosing scheme (50%–25%–25%) monitored by blood sampling.Objective and hypotheses: We describe the individualized optimization of HC treatment by 17-OHP saliva profiles and the effects of the res...

hrp0086p1-p142 | Bone & Mineral Metabolism P1 | ESPE2016

Effect of Bisphosphonates and Denosumab on Trabecular Bone: Results of a Pilot Study in Children with Osteogenesis Imperfecta

Rehberg Mirko , Semler Oliver , Hoyer-Kuhn Heike , Schonau Eckhard , Winzenrieth Renaud

Background: Osteogenesis imperfecta (OI) is a hereditary connective tissue disorder due to mutations related to collagen type 1. OI presents itself with low bone mass, resulting in high bone fragility. Bone mass is relevant for determination of the severity of OI. Although bisphosphonate treatment is able to increase areal bone mineral density (aBMD) measured by DXA, there is no correlation to fracture rates.Objective and hypotheses: The aim of this stud...

hrp0086p2-p643 | Growth P2 | ESPE2016

An Analysis of the Safety of Childhood Growth Hormone (GH) Therapy: Data from the NordiNet® International Outcome Study (IOS)

Savendahl Lars , Rohrer Tilman R , Pournara Effie , Pedersen Birgitte Tonnes , Blankenstein Oliver

Background: NordiNet® IOS (NCT00960128), a non-interventional study, collects long-term effectiveness and safety data of GH (Norditropin®, Novo Nordisk) treatment in everyday clinical practice.Objective and hypotheses: Identify paediatric patients more likely to experience a second adverse event (AE).Method: Based on diagnosis at GH treatment start and associated risk for mortality, patients were cla...

hrp0086p1-p743 | Pituitary and Neuroendocrinology P1 | ESPE2016

Proton Therapy as a Promising Therapeutic Option for Children with Aggressive and Uncontrolled Pituitary Macro Adenoma: A Case Report

Petit Isabelle Oliver , Bertozzi Anne-Isabelle , Boetto Sergio , Sevely Annick , Tauber Maithe , Caron Philippe , Alapetite Claire

Background: Non functioning pituitary macro adenoma is rare during childhood. Therapeutic options are reduced to surgery and radiotherapy. Proton therapy is a particle therapy that uses a beam of protons to irradiate the tissue with the chief advantage that as a charged particle the dose is deposited over a narrow range and there is minimal exit dose.Objective and hypotheses: Proton therapy is largely used in France for paediatric craniopharyngiomas irra...

hrp0082p1-d3-56 | Bone (1) | ESPE2014

Effect of a Vibration Based Rehabilitation Concept On Bone and Muscle Development in Children with Osteogenesis Imperfecta

Semler Oliver , Hoyer-Kuhn Heike , Stark Christina , Struebing Nora , Goebel Oranna , Schoenau Eckhard

Introduction: Osteogenesis imperfecta is a rare disease leading to immobility by recurrent fractures, hyperlaxicity of ligaments, short stature and muscular weakness. Beside drug treatment and surgical procedures physiotherapy is one of the most important treatment approaches to increase mobility. The objective of our analysis was to evaluate the effect of a new standardized 12 months physiotherapy concept including whole body vibration over 6 months on motor function and bone...